Treatment Approaches in Multiple Myeloma
Panelists discuss how advancements in treatment options, including chimeric antigen receptor (CAR) T-cell therapy, bispecific antibodies, and antibody-drug conjugates, are shaping the current multiple myeloma landscape.
The session begins with an overview of the evolving treatment landscape for multiple myeloma, emphasizing the integration of various therapeutic classes. These include immunomodulatory agents such as lenalidomide, proteasome inhibitors such as bortezomib, and monoclonal antibodies targeting CD38. More recent advances such as bispecific antibodies, CAR T-cell therapies, and antibody-drug conjugates have transformed treatment strategies.
The focus of the discussion is the 5-year update of the CARTITUDE-1 study evaluating CAR T-cell therapy, specifically ciltacabtagene autoleucel, in relapsed/refractory multiple myeloma. This trial marks a pivotal development in managing patients with limited options following multiple lines of prior therapy.
The panel underscores the significance of CAR T-cell therapy in the broader context of disease management. With increasing therapeutic options and ongoing innovation, there is growing optimism around not only improving survival but possibly achieving long-term remission or cure in a subset of patients.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
